Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Valeant Pharmaceuticals has sweetened its offer to buy specialty drugmaker Allergan to $50 billion in an effort to persuade Allergan’s board to agree to the deal. Like Valeant’s original $47 billion offer at the end of April, the new bid is backed by activist investor William A. Ackman. Separately, Valeant said it will sell a portfolio of dermatology drugs to Nestlé for $1.4 billion. The sale would remove some regulatory concerns over Valeant’s combination with Allergan, which makes the wrinkle-reducing drug Botox.
This article has been sent to the following recipient: